Deals this week: CF PharmaTech, Aurealis Pharma, aTyr Pharma


CF PharmaTech has secured $65m in a series D financing round led by SDIC. The Chinese respiratory drug developer plans to use the funds for the development of inhalation products.

Finnish biopharmaceutical company Aurealis Pharma has secured Sfr5.6m ($5.8m) in series A financing round led by Finnvera and Tekes.

The company plans to use the funds to progress the development of its chronic wound treatment and cancer drugs AUP-16 and AUP-5550 into clinical safety and efficacy trials.

"aTyr Pharma plans to raise $45.8m through the private placement of its common stock shares and Class X Preferred Stock."

aTyr Pharma plans to raise $45.8m through the private placement of its common stock shares and Class X Preferred Stock.

Based in the US, aTyr is a biotherapeutics company focused on the development of physiocrine-based therapeutics.

The company plans to use the funds to progress the development of its therapeutic candidate programmes and for general corporate purposes.